CD8A and neoplasm: A cys-diabody was also created using the variable regions of CD8 mAb YTS169.4.2.1 conjugated to 89Zr, which showed specificity and tracked CD8+ T cells in response to three different murine models of tumor immunotherapy: adoptive transfer of antigen-specific T cells, antagonist antibody, and checkpoint blockade (90).